search icon
glue-img

Monte Rosa Therapeutics Inc, Common Stock

GLUE

NSQ

$4.085

-$0.15

(-3.55%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$249.11M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
35.25
Volume info-icon
This is the total number of shares traded during the most recent trading day.
199.96K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.52
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$3.21 L
$12.4 H
$4.085

About Monte Rosa Therapeutics Inc, Common Stock

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3 inflammasome. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. to discover and develop MGDs against targets in cancer and neurological diseases. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameGLUESectorS&P500
1-Week Return4.44%1.39%1.18%
1-Month Return-11.69%-4.97%6.44%
3-Month Return-23.09%-11.13%-0.73%
6-Month Return-59.17%-10.21%-2.01%
1-Year Return5.75%-6.5%12.12%
3-Year Return-45.35%0.1%42.84%
5-Year Return-80.03%28.49%93.86%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue----75.62M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue537.00K2.13M8.56M6.22M8.12M[{"date":"2020-12-31","value":6.27,"profit":true},{"date":"2021-12-31","value":24.91,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":72.7,"profit":true},{"date":"2024-12-31","value":94.88,"profit":true}]
Gross Profit(537.00K)(2.13M)(8.56M)(6.22M)67.50M[{"date":"2020-12-31","value":-0.8,"profit":false},{"date":"2021-12-31","value":-3.16,"profit":false},{"date":"2022-12-31","value":-12.68,"profit":false},{"date":"2023-12-31","value":-9.22,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin----89.26%[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses28.01M72.88M112.38M143.31M156.73M[{"date":"2020-12-31","value":17.87,"profit":true},{"date":"2021-12-31","value":46.5,"profit":true},{"date":"2022-12-31","value":71.7,"profit":true},{"date":"2023-12-31","value":91.44,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(28.01M)(72.88M)(112.38M)(143.31M)(81.11M)[{"date":"2020-12-31","value":-2801000000,"profit":false},{"date":"2021-12-31","value":-7288200000,"profit":false},{"date":"2022-12-31","value":-11238400000,"profit":false},{"date":"2023-12-31","value":-14331100000,"profit":false},{"date":"2024-12-31","value":-8111200000,"profit":false}]
Total Non-Operating Income/Expense(7.86M)(1.03M)7.65M17.25M21.55M[{"date":"2020-12-31","value":-36.48,"profit":false},{"date":"2021-12-31","value":-4.78,"profit":false},{"date":"2022-12-31","value":35.49,"profit":true},{"date":"2023-12-31","value":80.07,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(35.88M)(73.96M)(108.50M)(135.01M)(70.13M)[{"date":"2020-12-31","value":-3587900000,"profit":false},{"date":"2021-12-31","value":-7395800000,"profit":false},{"date":"2022-12-31","value":-10850100000,"profit":false},{"date":"2023-12-31","value":-13501400000,"profit":false},{"date":"2024-12-31","value":-7013000000,"profit":false}]
Income Taxes189.00K(2.02M)(3.88M)338.00K2.57M[{"date":"2020-12-31","value":7.35,"profit":true},{"date":"2021-12-31","value":-78.44,"profit":false},{"date":"2022-12-31","value":-151.09,"profit":false},{"date":"2023-12-31","value":13.15,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Income After Taxes(36.07M)(71.94M)(104.62M)(135.35M)(72.70M)[{"date":"2020-12-31","value":-3606800000,"profit":false},{"date":"2021-12-31","value":-7194200000,"profit":false},{"date":"2022-12-31","value":-10461800000,"profit":false},{"date":"2023-12-31","value":-13535200000,"profit":false},{"date":"2024-12-31","value":-7270000000,"profit":false}]
Income From Continuous Operations(35.88M)(73.96M)(108.50M)(132.88M)(72.70M)[{"date":"2020-12-31","value":-3587900000,"profit":false},{"date":"2021-12-31","value":-7395800000,"profit":false},{"date":"2022-12-31","value":-10850100000,"profit":false},{"date":"2023-12-31","value":-13288200000,"profit":false},{"date":"2024-12-31","value":-7270000000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(36.07M)(71.94M)(104.62M)(135.35M)(72.70M)[{"date":"2020-12-31","value":-3606800000,"profit":false},{"date":"2021-12-31","value":-7194200000,"profit":false},{"date":"2022-12-31","value":-10461800000,"profit":false},{"date":"2023-12-31","value":-13535200000,"profit":false},{"date":"2024-12-31","value":-7270000000,"profit":false}]
EPS (Diluted)(7.18)(8.05)(2.29)(2.64)(0.98)[{"date":"2020-12-31","value":-718.22,"profit":false},{"date":"2021-12-31","value":-805,"profit":false},{"date":"2022-12-31","value":-229,"profit":false},{"date":"2023-12-31","value":-264,"profit":false},{"date":"2024-12-31","value":-98,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

GLUE
Cash Ratio 5.51
Current Ratio 5.61

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

GLUE
ROA (LTM) -0.40%
ROE (LTM) 2.88%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

GLUE
Debt Ratio Lower is generally better. Negative is bad. 0.30
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.70

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

GLUE
Trailing PE 35.25
Forward PE NM
P/S (TTM) 1.63
P/B 0.95
Price/FCF NM
EV/R 28.78
EV/Ebitda NM

FAQs

What is Monte Rosa Therapeutics Inc share price today?

Monte Rosa Therapeutics Inc (GLUE) share price today is $4.085

Can Indians buy Monte Rosa Therapeutics Inc shares?

Yes, Indians can buy shares of Monte Rosa Therapeutics Inc (GLUE) on Vested. To buy Monte Rosa Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GLUE stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Monte Rosa Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Monte Rosa Therapeutics Inc (GLUE) via the Vested app. You can start investing in Monte Rosa Therapeutics Inc (GLUE) with a minimum investment of $1.

How to invest in Monte Rosa Therapeutics Inc shares from India?

You can invest in shares of Monte Rosa Therapeutics Inc (GLUE) via Vested in three simple steps:

  • Click on Sign Up or Invest in GLUE stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Monte Rosa Therapeutics Inc shares
What is Monte Rosa Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Monte Rosa Therapeutics Inc (GLUE) is $12.4. The 52-week low price of Monte Rosa Therapeutics Inc (GLUE) is $3.21.

What is Monte Rosa Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Monte Rosa Therapeutics Inc (GLUE) is 35.25

What is Monte Rosa Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Monte Rosa Therapeutics Inc (GLUE) is 0.95

What is the Market Cap of Monte Rosa Therapeutics Inc?

The market capitalization of Monte Rosa Therapeutics Inc (GLUE) is $249.11M

What is Monte Rosa Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Monte Rosa Therapeutics Inc is GLUE

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top